Seer Operating Income 2021-2022 | SEER

Seer operating income from 2021 to 2022. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
Seer Annual Operating Income
(Millions of US $)
2021 $
2020 $
Seer Quarterly Operating Income
(Millions of US $)
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.445B $0.007B
Seer Inc. is a life sciences company. It engages in developing Proteograph(TM), which is an integrated solution consisting of consumables, automation instrumentation and proprietary software. Seer Inc. is based in REDWOOD CITY, Calif.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $164.215B 9.99
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.343B 16.33
Biohaven Pharmaceutical Holding (BHVN) United States $10.057B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.540B 0.00
Emergent Biosolutions (EBS) United States $1.675B 7.17
Arcus Biosciences (RCUS) United States $1.287B 32.64
Myovant Sciences (MYOV) United Kingdom $0.927B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.486B 0.00
Gelesis Holdings (GLS) United States $0.347B 0.00
Zymeworks (ZYME) Canada $0.336B 0.00
Ambrx Biopharma (AMAM) United States $0.154B 0.00
Enzo Biochem (ENZ) United States $0.113B 23.10
SQZ Biotechnologies (SQZ) United States $0.094B 0.00